Manganese for Wound Healing and Connective Tissue Repair

Wound healing is a four-phase orchestration: hemostasis, inflammation, proliferation, and remodeling. Each phase requires intact connective tissue biochemistry, and manganese is a critical cofactor at multiple points in that biochemistry. Manganese activates prolidase, the dipeptidase that recycles proline from degraded collagen for use in new collagen synthesis — the rare inherited disorder prolidase deficiency produces severe non-healing skin ulcers and demonstrates how essential this single enzyme is for tissue repair. Manganese also activates the family of glycosyltransferases that assemble the proteoglycan ground substance (chondroitin sulfate, hyaluronan) which provides the hydrated scaffold for fibroblast and keratinocyte migration into a wound bed. And MnSOD protects metabolically active fibroblasts and chondrocytes from the oxidative bursts that accompany inflammation. The result: wounds in manganese-deficient hosts heal more slowly, with weaker scar tensile strength and disorganized matrix.

Why Wound Healing Depends on Manganese
The Four Phases of Wound Healing
Prolidase: The Collagen-Recycling Enzyme
Prolidase Deficiency Syndrome: The Natural Experiment
Glycosyltransferases and the Provisional Wound Matrix
Chondrocyte Function and Cartilage Repair
MnSOD and the Inflammatory Phase
Angiogenesis and Granulation Tissue
Clinical Applications: Diabetic Wounds, Surgical Recovery, Burn Care
Dosing and Practical Considerations
Key Research Papers
Connections

Why Wound Healing Depends on Manganese

Connective tissue is structurally dominated by collagen (about 75% of dry weight of dermis) embedded in a ground substance of proteoglycans and glycosaminoglycans. When tissue is injured, both components must be replaced rapidly. The body's machinery for accomplishing this has three manganese-critical components:

Collagen substrate recycling — one-third of every collagen molecule is proline or hydroxyproline. The body has a limited capacity to synthesize proline de novo, so collagen turnover relies heavily on recycling proline from degraded collagen via prolidase. Prolidase is a manganese-activated enzyme.
Ground substance assembly — the proteoglycans (chondroitin sulfate, heparan sulfate, hyaluronan-binding aggrecan) that fill the matrix between collagen fibrils are built by manganese-dependent glycosyltransferases.
Cellular antioxidant defense — fibroblasts, chondrocytes, and endothelial cells engaged in active matrix synthesis have high mitochondrial activity. MnSOD in their mitochondria is the primary defense against the oxidative byproducts of that synthesis.

These three roles are layered. A manganese-deficient wound has slow collagen turnover (poor prolidase activity), weak ground substance (poor glycosyltransferase activity), and damaged matrix-producing cells (poor MnSOD activity). Each defect alone would slow healing; in combination, they produce a measurable clinical impairment.

Back to Table of Contents

The Four Phases of Wound Healing

Modern wound biology recognizes four temporally overlapping phases. Manganese contributes to each, but most prominently to phases 3 and 4.

Phase 1: Hemostasis (0–30 minutes) — platelets aggregate, fibrin clot forms, vasoconstriction limits blood loss. Vitamin K is the dominant micronutrient at this stage; manganese plays only a peripheral role.
Phase 2: Inflammation (1–72 hours) — neutrophils and macrophages migrate into the wound, phagocytose debris and bacteria, and orchestrate the next phase through cytokine release. MnSOD becomes important here because the respiratory burst of activated phagocytes generates substantial superoxide that, while necessary for pathogen killing, can damage surrounding healthy tissue if not contained.
Phase 3: Proliferation (3 days to 3 weeks) — fibroblasts migrate into the wound bed, lay down provisional matrix (hyaluronan, fibronectin), and begin synthesizing new collagen. Keratinocytes migrate across the wound surface to re-epithelialize. New blood vessels form (angiogenesis). This is where manganese-dependent glycosyltransferases (for ground substance) and prolidase (for collagen recycling) become indispensable.
Phase 4: Remodeling (3 weeks to 1+ years) — the initial Type III collagen of the early scar is progressively replaced by stronger Type I collagen, cross-linking matures, and the scar gains tensile strength (eventually reaching about 70-80% of original skin strength). Prolidase activity sustains the proline supply for this prolonged remodeling. MnSOD continues to protect the metabolically active remodeling cells.

Back to Table of Contents

Prolidase: The Collagen-Recycling Enzyme

Prolidase (also called peptidase D, PEPD, or imidodipeptidase) is a cytosolic metallopeptidase that hydrolyzes dipeptides containing C-terminal proline or hydroxyproline. It is the final step of collagen catabolism: collagen is degraded by collagenases (MMPs) to small peptides, those peptides are further hydrolyzed by general peptidases to amino acid pairs ending in proline (since proline is so frequent in collagen), and prolidase cleaves the last bond to release free proline.

Manganese activation — prolidase requires two manganese ions at its active site for catalytic activity. Loss of manganese binding inactivates the enzyme. This was one of the early findings establishing manganese's role in connective tissue.
Substrate range — the canonical substrate is Gly-Pro (glycyl-proline), the dominant imidodipeptide generated from collagen degradation. Prolidase also accepts His-Pro, Lys-Pro, Tyr-Pro, and most other X-Pro dipeptides.
Free proline output — the released proline is taken up by cells and channelled into multiple pathways: re-incorporation into new collagen (the major fate), conversion to hydroxyproline for collagen (after collagen translation, prolyl-4-hydroxylase converts certain proline residues to hydroxyproline within the assembled chain), and entry into other metabolic pathways (synthesis of glutamate, alpha-ketoglutarate, ornithine).
Tissue expression — prolidase is widely expressed but particularly active in skin fibroblasts, dermal papillae, chondrocytes, and intestinal epithelium. These are also the tissues with highest collagen turnover.
Beyond collagen — prolidase also participates in receptor signaling; PEPD has been identified as a ligand for the ErbB1/ErbB2 receptors with growth-factor-like activity independent of its enzymatic role.

Back to Table of Contents

Prolidase Deficiency Syndrome: The Natural Experiment

The clinical importance of prolidase is most clearly seen in the rare autosomal recessive disorder of prolidase deficiency (OMIM 170100), caused by loss-of-function mutations in the PEPD gene. Patients have essentially absent prolidase activity and accumulate iminodipeptides in plasma and urine (massive imidodipeptiduria is the diagnostic finding).

The clinical phenotype is striking and centers on skin and connective tissue:

Severe, chronic, non-healing leg ulcers — the cardinal feature. Patients develop skin ulcers in childhood that fail to heal despite aggressive wound care, often becoming chronically infected, and persisting for decades. The mechanism: cells in the wound bed cannot recycle proline from the damaged collagen that needs replacement, so collagen deposition cannot keep pace with collagen breakdown.
Facial dysmorphism — prominent forehead, hypertelorism, saddle nose, micrognathia
Splenomegaly — in many cases
Intellectual disability — in some patients
Recurrent respiratory infection — possibly related to altered immune function

The disorder is essentially untreatable in any curative sense, but case reports have described improvement in ulcer healing with topical proline supplementation, oral proline + vitamin C + manganese (to maximize residual prolidase function), and aggressive wound bed preparation. The natural experiment confirms: without functioning prolidase, wound healing fundamentally fails.

The clinical translation for the much more common situation of marginal manganese status is that suboptimal prolidase activity (even at 30-50% of optimum) slows wound healing without producing the full prolidase deficiency phenotype. Diabetic foot ulcer patients, pressure ulcer patients, and elderly post-surgical patients are populations where attention to manganese status may meaningfully improve outcomes.

Back to Table of Contents

Glycosyltransferases and the Provisional Wound Matrix

Within hours of injury, the wound bed fills with a provisional matrix dominated by fibrin (from the initial clot) and hyaluronan (synthesized by fibroblasts and endothelial cells migrating in). Over the following days, this provisional matrix is progressively replaced by a more permanent matrix of collagen, decorin, biglycan, and chondroitin-sulfate proteoglycans.

Manganese-dependent glycosyltransferases assemble the GAG side chains on these proteoglycans:

Hyaluronan synthases (HAS1, HAS2, HAS3) — produce hyaluronan, the major early wound matrix component. While the HAS enzymes themselves are not strictly manganese-dependent, the synthesis of their precursor UDP-sugars and the broader GAG biosynthesis network rely on manganese-activated steps.
Xylosyltransferase + galactosyltransferases — build the linker tetrasaccharide that connects GAG chains to proteoglycan core proteins. Strictly manganese-dependent.
N-acetylglucosaminyltransferases — build the repeating disaccharide backbone of heparan sulfate chains, which are essential for fibroblast growth factor (FGF) signaling that drives proliferation phase healing.
Chondroitin-sulfate-assembly enzymes — manganese-dependent, build the chondroitin sulfate side chains of decorin, biglycan, and versican. These proteoglycans organize the late-phase collagen fibril network.

Adequate ground substance is essential for fibroblast and keratinocyte migration. Cells migrate along proteoglycan and fibronectin tracks; an under-built matrix produces slower cellular migration and delayed re-epithelialization.

Back to Table of Contents

Chondrocyte Function and Cartilage Repair

Cartilage repair is qualitatively different from skin repair because of cartilage's avascularity. Articular cartilage has no blood supply, limited cellular density, and a very slow matrix turnover rate. When cartilage is damaged, the resident chondrocyte population must do all of the repair work itself, and chondrocyte function depends critically on manganese.

Chondrocyte matrix synthesis — chondrocytes produce aggrecan (manganese-dependent GAG assembly), Type II collagen (proline-rich, manganese-dependent recycling), and the small leucine-rich proteoglycans (decorin, biglycan, fibromodulin). All of this synthesis requires manganese cofactors.
Antioxidant protection — cartilage operates in a relatively hypoxic environment but with substantial mitochondrial activity per cell. MnSOD is the principal protector of chondrocyte mitochondria.
Response to mechanical load — chondrocytes sense and respond to mechanical compression through mechanotransduction pathways. Healthy chondrocytes respond to moderate cyclic loading with increased aggrecan synthesis; manganese-deficient or oxidatively stressed chondrocytes show blunted responses.
Osteoarthritis — the most prevalent chronic articular condition. Cartilage degradation in OA exceeds chondrocyte synthetic capacity. Manganese is sometimes included in joint-support formulations alongside glucosamine and chondroitin, on the rationale that providing both the building blocks (glucosamine, chondroitin) and the cofactors (manganese) gives chondrocytes the best chance of mounting matrix-synthesizing responses. The clinical-trial evidence for this combination is mixed but mechanistically reasonable.
Sports injury cartilage repair — meniscal injury, focal chondral defects, and post-traumatic arthritis all involve cartilage repair attempts. Manganese adequacy is one of the dietary inputs that can be optimized to support these processes, alongside dietary collagen peptides, vitamin C (for prolyl hydroxylase), and zinc.

For the broader manganese-cartilage story, see also the manganese and bone formation deep-dive on endochondral ossification.

Back to Table of Contents

MnSOD and the Inflammatory Phase

The inflammatory phase of wound healing is necessary but double-edged. Activated neutrophils and macrophages produce massive amounts of superoxide via the NADPH oxidase respiratory burst as their primary antibacterial weapon. This superoxide is essential for killing invading bacteria, but it also damages surrounding host tissue if not contained.

MnSOD in the mitochondria of neighboring fibroblasts, endothelial cells, and uninjured keratinocytes provides containment. When MnSOD is adequate, the oxidative damage is localized to the immediate inflammatory zone, and the surrounding tissue remains healthy and ready to enter the proliferation phase. When MnSOD is inadequate, oxidative damage spreads, healthy tissue is collateral damage, and the inflammation phase prolongs into a chronic non-healing state.

This is the mechanistic explanation for one of the most stubborn problems in wound care: chronic non-healing wounds (diabetic foot ulcers, venous stasis ulcers, pressure ulcers) often appear "stuck" in the inflammatory phase, with persistent infiltration of neutrophils, ongoing oxidative damage, and failure to transition to proliferation. Multiple inputs can contribute (poor perfusion, infection, repeated mechanical injury), but inadequate cellular antioxidant defense is consistently part of the picture.

The therapeutic implication is supporting the host's antioxidant defenses (MnSOD via manganese, glutathione via cysteine and glycine, vitamin E, vitamin C, selenium) as part of comprehensive chronic-wound care. For deeper coverage of the MnSOD mechanism, see the antioxidant MnSOD deep-dive.

Back to Table of Contents

Angiogenesis and Granulation Tissue

The proliferation phase of wound healing is characterized by the formation of granulation tissue — a pink, beefy, friable matrix consisting of newly forming capillaries, fibroblasts, and provisional extracellular matrix. The capillary network of granulation tissue forms through angiogenesis, in which endothelial cells from existing wound-edge vessels sprout into the wound bed.

Manganese supports angiogenesis through several routes:

MnSOD protection of newly forming endothelial cells — sprouting endothelium is exposed to the high-oxygen, high-oxidative environment of the wound. MnSOD adequacy protects these vulnerable new vessels from oxidative damage.
Heparan sulfate proteoglycan synthesis — the proteoglycans on endothelial surfaces are essential for binding and presenting angiogenic growth factors (VEGF, FGF). Manganese-dependent glycosyltransferases build these heparan sulfate chains.
Hypoxia-inducible factor coupling — some evidence suggests manganese availability modulates HIF-1alpha stability and the downstream VEGF transcription response, though this remains an active research area.

Back to Table of Contents

Clinical Applications: Diabetic Wounds, Surgical Recovery, Burn Care

Diabetic foot ulcers — one of the most challenging chronic wound problems, with annual incidence of 6–8% in diabetic populations and 5-year mortality after major amputation exceeding that of most cancers. Diabetic wounds combine impaired perfusion, neuropathic-loss-of-protection, chronic inflammation, and impaired cellular function. Patients are often deficient in zinc, vitamin C, and trace minerals including manganese. Comprehensive nutritional repletion as part of multimodal wound care has support in the literature.
Venous stasis ulcers — chronic lower-extremity ulcers from venous hypertension. Similar issues with chronic inflammation and impaired matrix synthesis. Compression therapy is the primary intervention; nutritional support is adjunctive.
Pressure ulcers — mechanical pressure causes localized ischemia, then necrosis, then a deep wound that requires complete reconstruction of dermis. Elderly patients, often nutritionally depleted, are the typical population. Comprehensive nutrient support (protein, vitamin C, zinc, manganese, vitamin A) accelerates healing in randomized trials.
Surgical wound healing — in elective surgery, prehabilitation with nutritional optimization for 2-4 weeks before operation has emerging evidence of benefit. Repletion of trace minerals is part of this. Particularly relevant for plastic and reconstructive surgery, where scar quality matters cosmetically.
Burn care — severe burns generate massive trace mineral losses through wound exudate and dramatically increased metabolic demands. ASPEN and ESPEN guidelines recommend trace mineral supplementation including manganese during burn recovery. The Heyland metabolic regimen for severe burn patients explicitly includes manganese alongside zinc, copper, and selenium.
Athletic soft-tissue injury — tendinopathy, ligament strain, muscle tear recovery. Less studied than the major clinical contexts above, but the same mechanisms apply: collagen turnover, ground substance synthesis, antioxidant protection of recovering cells.

Back to Table of Contents

Dosing and Practical Considerations

Background adequacy — 1.8-2.3 mg/day from diet is the foundation. For active wound healing, the requirement may be modestly elevated but rarely exceeds 5 mg/day from all sources.
Comprehensive wound-healing nutrition support — for chronic non-healing wounds, a multinutrient approach is more evidence-based than single-nutrient supplementation. Typical regimen: protein 1.2-1.5 g/kg/day, vitamin C 500-1000 mg/day, zinc 15-25 mg/day, vitamin A 5,000-10,000 IU/day (short-term), manganese 2-5 mg/day, vitamin E 200-400 IU/day, plus adequate B vitamins.
Topical proline + manganese — case reports in prolidase deficiency. Not generally applicable to ordinary wounds, but illustrates the mechanism.
Avoid excess — do not exceed 11 mg/day total manganese from all sources. Excessive manganese intake does not accelerate wound healing beyond baseline adequacy and risks neurotoxicity.
Patients with biliary obstruction or advanced liver disease — cannot excrete manganese normally. Even modest supplementation may cause CNS accumulation. Use other wound-supportive nutrients preferentially.
Drug interactions — antacids, tetracyclines, and quinolone antibiotics complex with manganese in the gut. Separate doses by 2 hours.

This content is provided for informational purposes only and does not constitute medical advice. Patients with chronic non-healing wounds should be evaluated by a wound-care specialist; nutritional support is one component of multimodal care.

Back to Table of Contents

Key Research Papers

Lupi A et al. (2008). Human recombinant prolidase from eukaryotic Pichia pastoris and prokaryotic Escherichia coli systems. Biotechnology and Applied Biochemistry 51(Pt 1):31-37. — PubMed
Phang JM, Liu W (2012). Proline metabolism and cancer. Frontiers in Bioscience. — PubMed
Kitchener RL, Grunden AM (2012). Prolidase function in proline metabolism and its medical and biotechnological applications. Journal of Applied Microbiology 113(2):233-247. — PubMed
Lupi A, Tenni R, Rossi A, Cetta G, Forlino A (2008). Human prolidase and prolidase deficiency. Amino Acids 35(4):739-752. — PubMed
Powell GF, Maniscalco RM (1976). Bound hydroxyproline excretion following gelatin loading in prolidase deficiency. Metabolism 25(5):503-508. — PubMed
Heyland DK et al. (2005). Antioxidant nutrients: a systematic review of trace elements and vitamins in the critically ill patient. Intensive Care Medicine 31(3):327-337. — PubMed
Berger MM, Shenkin A (2007). Trace element requirements in critically ill burned patients. Journal of Trace Elements in Medicine and Biology 21 Suppl 1:44-48. — PubMed
Stechmiller JK (2010). Understanding the role of nutrition and wound healing. Nutrition in Clinical Practice 25(1):61-68. — PubMed
Posthauer ME et al. (2015). The role of nutrition for pressure ulcer management: National Pressure Ulcer Advisory Panel, European Pressure Ulcer Advisory Panel, and Pan Pacific Pressure Injury Alliance white paper. Advances in Skin & Wound Care 28(4):175-188. — PubMed
Reiber GE, Vileikyte L, Boyko EJ et al. (1999). Causal pathways for incident lower-extremity ulcers in patients with diabetes from two settings. Diabetes Care 22(1):157-162. — PubMed
Hurley LS, Keen CL (1987). Manganese. In: Trace Elements in Human and Animal Nutrition. — PubMed
Leach RM, Muenster AM, Wien EM (1969). Studies on the role of manganese in bone formation. II. Effect upon chondroitin sulfate synthesis in chick epiphyseal cartilage. Archives of Biochemistry and Biophysics 133(1):22-28. — PubMed

PubMed Topic Searches

Back to Table of Contents

Connections

Back to Table of Contents